Bayer HealthCare / Press

Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children

BAY 81-8973 is a full-length recombinant factor VIII which has demonstrated clinical evidence of efficacy when used in standard dosage for prophylaxis two times or three times per week. more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.

  • TV Footage

    In this section you can find videos for editorial coverage.

Bayer HealthCare Links

Annual report Integrated Annual Report of Bayer AG 2013
RSS Feed
RSS Feed

Copyright © Bayer HealthCare AG